Tissue Polypeptide Specific Antigen (TPS®) detection kit for Breast Prostate and Ovarian cancer

Tissue peptide-specific antigen TPS, a specific indicator of proliferative activity of tumor cells

An earlier insight into tumor change

^{The tumor marker TPS® is a reliable indicator of tumor cell activity particularly useful in patient manage-ment for different carcinomas. Compared with conventional tumor mass markers, the activity marker TPS®        provides the clinician with earlier signals about the course of the disease. TPS® is particularly useful in treatment monitoring and surveillance of patients with epithelial cell carcinomas e.g. breast, prostate and ovarian cancer.}

A TUMOR MARKER FOR PATIENT MANAGEMENT

^{1. Particularly useful in patient management for carcinomas of different origins}

^{2. Provides the clinician with earlier signals about the course of the disease when compared to}

^{clinical criteria}

^{3. In combination with conventional tumor mass markers gives a more complete}

^{clinical picture, thus making it possible for the clinician to act with greater insight}

^{4. Serves as a tool for the prediction of treatment outcome}

^{5. High sensitivity for metastatic disease}

^{6. Supports therapeutical decisions to optimize patient management and improve the}

^cost/benefit

^{7. Reliable indicator of tumor cell activity, especially useful in treatment monitoring and}

^{patient follow-up.}

                                               Breast cancer

^{TPS® has consistently been found to be a good marker for prediction of prognosis and response to therapy. By serial testing, TPS® can be used for therapy control and follow-up of breast cancer patients. The sensitivity of TPS® to detect progressive disease is particularly high in patients with metastatic spread. Pretreatment TPS® levels have been shown to be related to prognosis and clinical outcome.}

Prostate cancer

^{The cytokeratin marker TPS® can provide the clinician with an important complementary tool to PSA, especially in patients following androgen-suppressive hormonal therapy. TPS® has been shown to clearly differentiate between stable and progressive disease and may consequently be used as an early indicator of the efficiency of treatment.}

Ovarian cancer

^{TPS® can be used as a prognostic indicator of clinical outcome in patients with advanced ovarian cancer. Due to its high sensitivity for progressive disease, the activity marker TPS® also provides useful supplementary information to other markers. Clinical reports show an increase in prognosis efficiency using the combination of CA125 and TPS® for patient monitoring. The addition of TPS® improves the clinical decision-making and overall patient management for ovarian cancer.}